CAMPTO 20 mg/mL concentrate for solution for infusion clinical trials

A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

This study looks at a new drug, magrolimab, combined with standard treatments for advanced bowel cancer that has spread and can't be operated on. It aims to see if this new combination is safe and helps people live longer without their cancer getting worse.